HR6994-119

What This Bill Does

The Mental Health TALK SAFE Act amends the Controlled Substances Act and related state-law treatment for telehealth mental health care. For approved mental health controlled substances, a telehealth practitioner may prescribe after at least one telehealth evaluation, and practitioners treating opioid use disorder may prescribe schedule II through V controlled substances after at least one telehealth evaluation. The bill defines approved mental health controlled substances, telehealth entities, exempt entities, health care providers, hospitals, federally qualified health centers, nonprofit organizations, interactive telecommunications systems, mental health disorders, telehealth evaluations, and related ownership and compensation restrictions. It allows a registrant dispensing through telemedicine or after a telehealth evaluation to avoid additional DEA registrations in each State where dispensing occurs, and lets qualifying telehealth practitioners use the telehealth entity address as their principal practice address. It treats covered psychiatrists licensed in a primary State as satisfying substantially similar secondary-State licensure requirements for covered psychiatry telehealth services, while preserving scope-of-practice limits and adjusting professional liability insurance treatment. Finally, it preempts State statutes, regulations, orders, or interpretations that directly or indirectly prohibit or restrict the Act's permitted activities.

Who Benefits and How

Patients with mental health disorders and patients with opioid use disorder benefit from easier access to telehealth prescribing when an in-person visit is unavailable or delayed. Telehealth psychiatrists, psychiatric clinicians, federally qualified health centers, hospitals, nonprofit providers, and compliant telehealth entities benefit from clearer prescribing, registration, and interstate-service rules. Covered psychiatrists benefit because a primary-State license can satisfy substantially similar secondary-State licensure requirements for remote covered psychiatry services. Pharmacies and patients may benefit if prescriptions are less likely to be rejected solely because telehealth evaluation supported them.

Who Bears the Burden and How

DEA registration and diversion-control staff must update controlled-substance registration, address, oversight, and enforcement systems for telehealth prescribing. State medical boards and State legislatures lose authority where their rules would restrict activities the Act permits, and must understand the federal preemption boundary. Telehealth entities must satisfy staffing, ownership, compensation, compliance, exempt-entity, and patient-volume conditions. Covered psychiatrists, liability insurers, and health systems must track primary-State, secondary-State, scope-of-practice, and insurance-coverage rules. Regulators and pharmacies must monitor diversion risk while allowing the newly permitted telehealth prescriptions.

Key Provisions

• Authorizes telehealth prescribing of approved mental health controlled substances after at least one telehealth evaluation.
• Authorizes telehealth prescribing of schedule II through V controlled substances for opioid-use-disorder treatment after at least one telehealth evaluation.
• Removes the need for additional DEA registrations in each State when dispensing occurs through telemedicine or after a telehealth evaluation.
• Allows qualifying telehealth practitioners to use a telehealth entity address as their principal practice address.
• Treats covered psychiatrists as satisfying substantially similar secondary-State licensure requirements for covered telepsychiatry services.
• Preempts State laws that directly or indirectly prohibit or restrict the activities permitted by the Act.